苦黄注射液预防抗结核药物导致的药物性肝损伤患者疗效研究OACSTPCD

Objective This study was to observe the Kuhuang,a herbal injection compound,in preventing anti-tuberculosis drugs(ATD)-induced liver injury(DILI)for avoiding unreasonable anti-tuberculosis treatment interruption.Methods A total of 97 patients with naïve pulmonary tuberculosis were encountered in our hospital between March 2022 and November 2022,and were randomly divided into control(n=47)and observation(n=50)groups,receiving standardized 2HREZ/4HR anti-tuberculosis therapy,or intravenous injection of Kuhuang compound at base of anti-tuberculosis for 8 weeks.Serum interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)levels were detected by ELISA,and serum heme oxygenase(HO-1)and superoxide dismutase(SOD)levels were detected by radioimmunoassay.Results At the end of 4 week anti-tuberculosis treatment,the incidences of adaptive liver injury(ALI)and DILI in the observation group were 6.0%and 2.0%,much lower than 17.0%and 8.5%(P<0.05)in the control,and at the end of 8 week treatment,the incidences of ALI and DILI were 6.0%and 4.0%,much lower than 21.3%and 17.0%(P<0.05)in the control group;at the end of 8 week treatment,serum ALT,AST and total bilirubin levels in the observation group were(28.4±23.4)U/L,(30.8±18.7)U/L and(12.9±7.3)μmol/L,all significantly lower than[(53.1±33.1)U/L,(52.5±37.7)U/L and(20.1±10.9)μmol/L,respectively,P<0.05]in the control;serum HO-1 and SOD levels were(200.3±14.0)U/L and(418.0±18.7)U/L,both significantly higher than[(128.8±21.4)U/L and(318.0±15.1)U/L,P<0.05],while serum IL-6 and TNF-α levels were(11.4±1.9)ng/L and(9.3±1.8)ng/L,both significantly lower than[(17.5±4.0)ng/L and(14.5±3.0)ng/L,respectively,P<0.05]in the control.Conclusion The administration of Kuhuang injection compound could prevent the occurrence of anti-tuberculosis DILI,and guarantee the standardized anti-tuberculosis treatment completing.